Heparin Label Update Aims to Clarify Dosage Strength

|

Federal drug regulators have ordered a warning label update for the blood thinner heparin, which is designed to better explain the drug’s dosage strengths. 

The FDA issued a drug safety communication on December 6, indicating that label changes will affect Heparain Lock Flush Solution, USP and Heparin Sodium Injection, USP.

The medications will be required to clearly stat the strength of the entire container, in addition to how much of the drug’s active ingredient is in a 1 milliliter (mL) dose.

Sports-Betting-Addiction-Lawsuits
Sports-Betting-Addiction-Lawsuits

The dosage strength on the old labels simply read: 5,000 USP units per mL. But the updated labels will read: 50,000 USP units per 10 mL (5,000 USP units per mL).

The FDA says the new labels will “eliminate the need for health care professionals to calculate the total amount of heparin medication in a product containing more than 1 mL, thereby reducing the risk of miscalculations that may result in medication errors.”

Concerns began surfacing about risks associated with heparin dosage labels in 2009. Manufacturers are required to have the new labels in place by May 1, 2013.

Written by: Irvin Jackson

Senior Legal Journalist & Contributing Editor

Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends.

Image Credit: |



0 Comments


This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

A federal judge is expected to decide which scientific experts each side may present during the early Depo-Provera meningioma test trials around the middle of next year.
A Texas couple has filed a ByHeart formula recall lawsuit after their four-month old contracted infant botulism days before the recall was announced.